Distribution of genetic alterations in high-risk early-stage cervical cancer patients treated with postoperative radiation therapy

2020 Fiscal Year Final Research Report

• Project/Area Number: 18K15654
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 52040:Radiological sciences-related
• Research Institution: National Cancer Center Japan
• Principal Investigator: Murakami Naoya 国立研究開発法人国立がん研究センター, 中央病院, 医長 (00604282)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Keywords: 子宮頸癌 / 広汎子宮全摘術 / 術後ハイリスク / 術後放射線治療 / 体細胞由来遺伝子変異

Outline of Final Research Achievements

Between January 2008 and November 2019, 89 patients who underwent abdominal radical hysterectomy followed by post-operative radiation therapy were identified. The follow-up period for living patients was 82.3 months (range, 9.3-153.9), and the 5-year relapse-free survival and overall survival rates were 72.6% and 85.9%, respectively. The most frequently detected somatic mutation was PIK3CA (26 [29.2%] patients); however, no prognostic somatic genetic alterations were identified. Actionable mutations were detected in 30 (33.7%) patients. Actionable mutations were detected in approximately one-third of patients, suggesting that precision medicine can be offered to patients with post-operative high-risk uterine cervical cancer in the near future.

Free Research Field

放射線腫瘍学

Academic Significance and Societal Importance of the Research Achievements

術後ハイリスク群に術後放射線治療を行った患者を対象とした今回の研究で、子宮頸癌の予後と相関するような遺伝子異常は見いだせなかったが、現時点でのdruggableなactionable mutationは約3割に確認されたのは大きな発見であると考える。今後、子宮頸癌の薬物療法にも分子標的薬が入ってくると思われるが、その際に基盤となる重要な知見が得られたものと考える。。